NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences.
Details of the Company’s participation are as follows:
Cantor Global Healthcare Conference 2025
Format: Fireside Chat
Date: Friday, September 5th at 8:35 a.m. ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Format: Fireside Chat
Date and Time: Monday, September 8th at 11:30 a.m. ET
Location: New York, NY
TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Format: Fireside Chat
Date and Time: Wednesday, September 17th at 10:00 a.m. ET
Location: Virtual
The webcasts for the fireside chat will be available on atai’s website under Events on the Investors section of the atai website. Replays will be available following the live events.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes BPL-003 (intranasal mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a strategic investment with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.
Contact Information
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.29 |
| Daily Change: | -0.16 -2.94 |
| Daily Volume: | 18,132,216 |
| Market Cap: | US$1.240B |
August 14, 2025 June 02, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
